Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.
Global control of tuberculosis (TB), an infectious disease that claims nearly 2 million lives annually, is hindered by the long duration of chemotherapy required for curative treatment. Lack of adherence to this intense treatment regimen leads to poor patient outcomes, development of new or addition...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2012-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3272040?pdf=render |
| _version_ | 1811296280886902784 |
|---|---|
| author | Mamoudou Maiga Nisheeth Agarwal Nicole C Ammerman Radhika Gupta Haidan Guo Marama C Maiga Shichun Lun William R Bishai |
| author_facet | Mamoudou Maiga Nisheeth Agarwal Nicole C Ammerman Radhika Gupta Haidan Guo Marama C Maiga Shichun Lun William R Bishai |
| author_sort | Mamoudou Maiga |
| collection | DOAJ |
| description | Global control of tuberculosis (TB), an infectious disease that claims nearly 2 million lives annually, is hindered by the long duration of chemotherapy required for curative treatment. Lack of adherence to this intense treatment regimen leads to poor patient outcomes, development of new or additional drug resistance, and continued spread of M.tb. within communities. Hence, shortening the duration of TB therapy could increase drug adherence and cure in TB patients. Here, we report that addition of the United Stated Food and Drug Administration-approved phosphodiesterase inhibitors (PDE-Is) cilostazol and sildenafil to the standard TB treatment regimen reduces tissue pathology, leads to faster bacterial clearance and shortens the time to lung sterilization by one month, compared to standard treatment alone, in a murine model of TB. Our data suggest that these PDE-Is could be repurposed for use as adjunctive drugs to shorten TB treatment in humans. |
| first_indexed | 2024-04-13T05:46:57Z |
| format | Article |
| id | doaj.art-c45d55d649754762bd933910f63cb276 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T05:46:57Z |
| publishDate | 2012-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-c45d55d649754762bd933910f63cb2762022-12-22T02:59:56ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0172e3074910.1371/journal.pone.0030749Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model.Mamoudou MaigaNisheeth AgarwalNicole C AmmermanRadhika GuptaHaidan GuoMarama C MaigaShichun LunWilliam R BishaiGlobal control of tuberculosis (TB), an infectious disease that claims nearly 2 million lives annually, is hindered by the long duration of chemotherapy required for curative treatment. Lack of adherence to this intense treatment regimen leads to poor patient outcomes, development of new or additional drug resistance, and continued spread of M.tb. within communities. Hence, shortening the duration of TB therapy could increase drug adherence and cure in TB patients. Here, we report that addition of the United Stated Food and Drug Administration-approved phosphodiesterase inhibitors (PDE-Is) cilostazol and sildenafil to the standard TB treatment regimen reduces tissue pathology, leads to faster bacterial clearance and shortens the time to lung sterilization by one month, compared to standard treatment alone, in a murine model of TB. Our data suggest that these PDE-Is could be repurposed for use as adjunctive drugs to shorten TB treatment in humans.http://europepmc.org/articles/PMC3272040?pdf=render |
| spellingShingle | Mamoudou Maiga Nisheeth Agarwal Nicole C Ammerman Radhika Gupta Haidan Guo Marama C Maiga Shichun Lun William R Bishai Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. PLoS ONE |
| title | Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. |
| title_full | Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. |
| title_fullStr | Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. |
| title_full_unstemmed | Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. |
| title_short | Successful shortening of tuberculosis treatment using adjuvant host-directed therapy with FDA-approved phosphodiesterase inhibitors in the mouse model. |
| title_sort | successful shortening of tuberculosis treatment using adjuvant host directed therapy with fda approved phosphodiesterase inhibitors in the mouse model |
| url | http://europepmc.org/articles/PMC3272040?pdf=render |
| work_keys_str_mv | AT mamoudoumaiga successfulshorteningoftuberculosistreatmentusingadjuvanthostdirectedtherapywithfdaapprovedphosphodiesteraseinhibitorsinthemousemodel AT nisheethagarwal successfulshorteningoftuberculosistreatmentusingadjuvanthostdirectedtherapywithfdaapprovedphosphodiesteraseinhibitorsinthemousemodel AT nicolecammerman successfulshorteningoftuberculosistreatmentusingadjuvanthostdirectedtherapywithfdaapprovedphosphodiesteraseinhibitorsinthemousemodel AT radhikagupta successfulshorteningoftuberculosistreatmentusingadjuvanthostdirectedtherapywithfdaapprovedphosphodiesteraseinhibitorsinthemousemodel AT haidanguo successfulshorteningoftuberculosistreatmentusingadjuvanthostdirectedtherapywithfdaapprovedphosphodiesteraseinhibitorsinthemousemodel AT maramacmaiga successfulshorteningoftuberculosistreatmentusingadjuvanthostdirectedtherapywithfdaapprovedphosphodiesteraseinhibitorsinthemousemodel AT shichunlun successfulshorteningoftuberculosistreatmentusingadjuvanthostdirectedtherapywithfdaapprovedphosphodiesteraseinhibitorsinthemousemodel AT williamrbishai successfulshorteningoftuberculosistreatmentusingadjuvanthostdirectedtherapywithfdaapprovedphosphodiesteraseinhibitorsinthemousemodel |